Hypotrichosis of the Eyelashes

• FDA approval · 2025-03-17
  FDA Approved: BIMATOPROST — Original Application (Lifestar Pharma LLC)

  FDA approved the original application for Bimatoprost by Lifestar Pharma LLC, granting approval for a generic ophthalmic solution intended t…

• FDA approval · 2024-02-13
  FDA Approved: BIMATOPROST — Supplemental Application (Apotex Corp.)

  The FDA approved a supplemental application for bimatoprost from Apotex Corp., authorizing a regulatory change under the ANDA framework.

• FDA approval · 2022-10-06
  FDA Approved: BIMATOPROST — Original Application (Aurobindo Pharma Limited)

  The FDA approved the Original Application for BIMATOPROST (bimatoprost) by Aurobindo Pharma Limited under ANDA205537.

• FDA approval · 2021-08-26
  FDA Approved: LATISSE — Supplemental Application (Allergan, Inc.)

  The FDA approved a supplemental application for LATISSE (bimatoprost) by Allergan, Inc. The document records the approval status of the supp…

• FDA approval · 2017-07-29
  FDA Approved: LATISSE — Supplemental Application (Allergan, Inc.)

  FDA approved Allergan's supplemental application for LATISSE (bimatoprost) to expand its labeling related to eyelash growth.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2013-11-01
  FDA Approved: LATISSE — Supplemental Application (Allergan, Inc.)

  FDA approved a supplemental application for LATISSE (bimatoprost) submitted by Allergan, Inc.

• FDA approval · 2013-03-13
  FDA Approved: LATISSE — Supplemental Application (Allergan, Inc.)

  FDA approved a supplemental application for LATISSE (bimatoprost) from Allergan, granting an approved supplemental indication/labeling for e…

• CLINICAL_TRIALS trial_result · 2012-09-19
  Clinical Trial Update: Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin [Phase 3]

  Phase 3 trial update evaluating the safety and efficacy of applying bimatoprost to the eyelid margin to treat hypotrichosis of the eyelashes…

• FDA approval · 2011-09-07
  FDA Approved: LATISSE — Supplemental Application (Allergan, Inc.)

  The FDA approved Allergan’s supplemental application for LATISSE (bimatoprost), expanding the product’s labeling for eyelash growth.

• FDA approval · 2008-12-24
  FDA Approved: LATISSE — Original Application (Allergan, Inc.)

  FDA approved LATISSE (bimatoprost) from Allergan for the treatment of hypotrichosis of the eyelashes to promote eyelash growth.